Safety Monitoring and Management for Acalabrutinib + Venetoclax in Chronic Lymphocytic Leukemia

Tumor‑Lysis‑Syndrome (TLS) Prevention

Weekly laboratory monitoring during the 5‑week venetoclax dose‑ramp (weeks 1‑5 of cycle 3) is mandatory to detect TLS (uric acid, potassium, phosphorus, calcium, creatinine). This monitoring reduces the risk of fatal TLS events. 1
Baseline assessment of tumor burden, renal function, and TLS risk must be performed before initiating venetoclax. Patients with high tumor burden or impaired renal function are classified as high‑risk. 2
High‑risk patients should receive adequate hydration and prophylactic agents (allopurinol or rasburicase) during the ramp‑up. These measures further mitigate TLS risk. 1
Hospitalization is recommended for high‑risk patients during the venetoclax ramp‑up to allow close monitoring and rapid intervention if TLS develops. 2
Skipping the venetoclax ramp‑up schedule, even when tumor burden appears low, is contraindicated because TLS can occur unpredictably and be fatal. 1

A comprehensive cardiac assessment is required for patients with pre‑existing cardiovascular disease before starting acalabrutinib. Although acalabrutinib has a lower arrhythmia risk than ibrutinib, monitoring for atrial fibrillation and hypertension remains essential. 2
Bleeding risk should be evaluated, especially in patients receiving concomitant anticoagulants or antiplatelet agents. This assessment guides decisions on dose adjustments or additional precautions. 1

If disease progression occurs on the acalabrutinib‑venetoclax regimen, the recommended next step is to switch to an alternative targeted‑therapy class (e.g., PI3K inhibitors or non‑covalent BTK inhibitors such as pirtobrutinib) rather than returning to chemoimmunotherapy. This strategy leverages different mechanisms of action to overcome resistance. 2